Aktienanalyse zu Progyny Inc (PGNY)PGNYProgyny Inc

Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Progyny Inc is a good buy right now due to its current price of $27.93, which is significantly below the analyst price target of $37 from Wells Fargo, indicating a potential upside of 45%. Additionally, the company has shown strong financial performance with a gross margin of 25.48% in Q2 2026 and a forward P/E ratio of 11.85, suggesting it is undervalued compared to its growth potential. However, a risk to consider is the insider selling activity, which has increased by 601.40% over the last month, indicating potential concerns among insiders about the stock's future performance.